Glycopyrronium Ethypharm

Glycopyrronium Ethypharm, containing the active ingredient glycopyrronium bromide, is an injectable medication supplied as a solution; the specific strength varies according to the prescribing information for each market. It belongs to the anticholinergic (muscarinic antagonist) class and is available by prescription in the European Union. The drug is given intravenously or intramuscularly under professional supervision to reduce salivary, respiratory and bronchial secretions during surgical procedures.

Glycopyrronium Ethypharm is indicated for use in the peri‑operative period to manage excessive secretions.

- Preoperative reduction of salivary secretions to facilitate airway management. - Decrease of respiratory tract secretions to improve ventilation during anesthesia. - Control of bronchial secretions in patients undergoing thoracic surgery. - Adjunctive use to reduce secretions in patients receiving anticholinergic therapy for other indications. - Facilitation of endotracheal intubation by minimizing oral and pharyngeal moisture.

The safety profile of glycopyrronium bromide includes both frequent mild effects and rare serious reactions.

Common: - Dry mouth - Throat irritation - Transient increase in heart rate - Mild facial flushing - Nausea

Serious: - Severe hypotension - Cardiac arrhythmias - Anaphylactic reaction - Acute urinary retention - Bronchospasm

When prescribing Glycopyrronium Ethypharm, clinicians should consider several precautionary measures to ensure patient safety.

- Assess for known hypersensitivity to glycopyrronium or other anticholinergics. - Use cautiously in patients with glaucoma, especially narrow‑angle type. - Monitor cardiovascular status in individuals with pre‑existing heart disease. - Avoid in patients with severe obstructive airway disease without specialist advice. - Adjust dose or observe closely in the elderly due to increased sensitivity. - Consider renal or hepatic impairment as it may affect drug clearance.

Glycopyrronium bromide may interact with other medications; awareness of these interactions helps prevent adverse effects.

Avoid: - Concurrent use with other anticholinergic agents (e.g., atropine, scopolamine) that may cause additive anticholinergic toxicity. - Combination with drugs that prolong QT interval, increasing risk of cardiac arrhythmias.

Use with caution: - Beta‑adrenergic agonists (e.g., albuterol) as they may enhance tachycardia. - Anesthetic agents such as succinylcholine, which may potentiate muscle relaxation. - Antihypertensive medications, requiring blood pressure monitoring. - Drugs affecting renal excretion, potentially altering glycopyrronium levels.